Abstract
It has been advocated that biopharmaceutic risk assessment should be conducted early in pediatric product development and synchronized with the adult product development program. However, we are unaware of efforts to classify drugs into a Biopharmaceutics Classification System (BCS) framework for pediatric patients. The objective was to classify five drugs into a potential BCS. These five drugs were selected since both oral and intravenous pharmacokinetic data were available for each drug, and covered the four BCS classes in adults. Literature searches for each drug were conducted using Medline and applied to classify drugs with respect to solubility and permeability in pediatric subpopulations. Four pediatric subpopulations were considered: neonates, infants, children, and adolescents. Regarding solubility, dose numbers were calculated using a volume for each subpopulation based on body surface area (BSA) relative to 250 ml for a 1.73 m2 adult. Dose numbers spanned a range of values, depending upon the pediatric dose formula and subpopulation. Regarding permeability, pharmacokinetic literature data required assumptions and decisions about data collection. Using a devised pediatric BCS framework, there was agreement in adult and pediatric BCS class for two drugs, azithromycin (class 3) and ciprofloxacin (class 4). There was discordance for the three drugs that have high adult permeability since all pediatric permeabilities were low: dolasetron (class 3 in pediatric), ketoprofen (class 4 in pediatric), and voriconazole (class 4 in pediatric). A main contribution of this work is the identification of critical factors required for a pediatric BCS.
Similar content being viewed by others
REFERENCES
Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. 2000. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070246.pdf. Accessed 21 May 2013.
Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413–20.
Polli JE. In vitro studies are sometimes better than conventional human pharmacokinetic in vivo studies in assessing bioequivalence of immediate-release solid oral dosage forms. AAPS J. 2008;10:289–99. doi:10.1208/s12248-008-9027-6.
Cook JA, Davit BM, Polli JE. Impact of biopharmaceutics classification system-based biowaivers. Mol Pharm. 2010;7:1539–44. doi:10.1021/mp1001747.
Purohit VS. Biopharmaceutic planning in pediatric drug development. AAPS J. 2012;4:519–22. doi:10.1208/s12248-012-9364-3.
Intra-Agency Agreement Between the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the U.S. Food and Drug Administration (FDA) Oral Formulations Platform—Report 1. 2011. http://bpca.nichd.nih.gov/collaborativeefforts/initiatives/upload/Formulations_Table_for_Web_11-02-11.pdf. Accessed 21 May 2013.
Hoff DS, Jensen PD. Pediatric pharmacotherapy. In: Hoff DS, Jensen PD, editors. Pharmacotherapy self-assessment program. 4th ed. Kansas City: American College of Clinical Pharmacy; 2003. p. 13.
Abdel-Rahman SM, Amidon GL, Kaul A, Lukacova V, Vinks AA, Knipp GT, et al. Summary of the National Institute of Child Health and Human Development—best pharmaceuticals for Children Act Pediatric Formulation Initiatives Workshop—Pediatric Biopharmaceutics Classification System Working Group. Clin Ther. 2012;34(11):S11–24. doi:10.1016/j.clinthera.2012.09.014.
ANZEMET® (dolasetron mesylate) Tablets. Sanofi-Aventis U.S. LLC. October 2003. http://products.sanofi.us/anzemet_tablets/anzemettab.pdf. Accessed 24 August 2013.
Kokki H, Tuomilehto H, Karvinen M. Pharmacokinetics of ketoprofen following oral and intramuscular administration in young children. Eur J Clin Pharmacol. 2001;57(9):643–7.
Neely M, Rushing T, Kovacs A, Jelliffe R, Hoffman J. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis. 2010;50(1):27–36.
ZITHROMAX® (azithromycin tablets and azithromycin for oral suspension). Pfizer Inc. February 2013. http://labeling.pfizer.com/ShowLabeling.aspx?id=511. Accessed 24 August 2013.
CIPRO® (Ciprofloxacin Hydrochloride) TABLETS, CIPRO® (Ciprofloxacin) ORAL SUSPENSION. Bayer HealthCare Pharmaceuticals Inc. 2008. http://www.univgraph.com/bayer/inserts/ciprotab.pdf Accessed 21 May 2013.
Benet LZ, Broccatelli F, Oprea TI. BDDCS applied to over 900 drugs. AAPS J. 2011;13:519–47.
Curatolo W. Interdisciplinary science and the design of a single-dose antibiotic therapy. Pharm Res. 2011;28(9):2059–71. doi:10.1007/s11095-011-0382-0.
Takagi T, Ramachandran C, Bermejo M, Yamashita S, Yu LX, Amidon GL. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. Mol Pharm. 2006;3(6):631–43.
Centers for Disease Control and Prevention. 2 to 20 years: Boys Stature-for-Age and Weight-for-Age Percentiles. 2000. http://www.cdc.gov/growthcharts/data/set1clinical/cj41c021.pdf Accessed 21 May 2013.
Centers for Disease Control and Prevention. Birth to 36 months: Boys Length-for-Age and Weight-for-Age Percentiles. 2000. http://www.cdc.gov/growthcharts/data/set1clinical/cj41l017.pdf Accessed 21 May 2013.
Coppes MJ, Yanofsky R, Pritchard S, Leclerc JM, Howard DR, Perrotta M, et al. Safety, tolerability, antiemetic efficacy, and pharmacokinetics of oral dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy. J Pediatr Hematol Oncol. 1999;21(4):274–83.
Driscoll TA, Yu LC, Frangoul H, Krance RA, Nemecek E, Blumer J, et al. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults. Antimicrob Agents Chemother. 2011;55(12):5770–9. doi:10.1128/AAC.00531-11.
Nahata MC, Koranyi KI, Luke DR, Foulds G. Pharmacokinetics of azithromycin in pediatric patients with acute otitis media. Antimicrob Agents Chemother. 1995;39(8):1875–7.
Schaefer HG, Stass H, Wedgwood J, Hampel B, Fischer C, Kuhlmann J, et al. Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients. Antimicrob Agents Chemother. 1996;40(1):29–34.
Coppes MJ, Lau R, Ingram LC, Wiernikowski JT, Grant R, Howard DR, et al. Open-label comparison of the antiemetic efficacy of single intravenous doses of dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy. Med Pediatr Oncol. 1999;33(2):99–105.
KETOPROFEN® capsule. Mylan Pharmaceuticals Inc. 2011. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=198a4140-f4c0-4478-9157-ee1d68d0bb96. Accessed 24 November 2013.
Kokki H, Karvinen M, Suhonen P. Pharmacokinetics of intravenous and rectal ketoprofen in young children. Clin Pharmacokinet. 2003;42(4):373–9.
Kokki H. Ketoprofen pharmacokinetics, efficacy, and tolerability in pediatric patients. Pediatr Drugs. 2010;12(5):313–29.
VFEND® (Voriconazole) Tablets, Oral Suspension. Pfizer Ireland Pharmaceutical 2011. http://labeling.pfizer.com/ShowLabeling.aspx?id=618. Accessed 24 November 2013.
Jacobs RF, Maples HD, Aranda JV, Espinoza GM, Knirsch C, Chandra R, et al. Pharmacokinetics of intravenously administered azithromycin in pediatric patients. Pediatr Infect Dis J. 2005;24(1):34–9.
Pelotas H. Single-dose and steady-state pharmacokinetics of a new oral suspension of ciprofloxacin in, children. Pediatrics. 1998;101(4):658.
Baines D. Postoperative nausea and vomiting in children. Paediatr Anaesth. 1996;6:7–14.
Sung Y. Risks and benefits of drugs used in the management of PONV. Drug Saf. 1996;14:181–97.
Olutoye O, Jantzen EC, Alexis R, Rajchert D, Schreiner MS, Watcha MF. A comparison of the costs and efficacy of ondansetron and dolasetron in the prophylaxis of postoperative vomiting in pediatric patients undergoing ambulatory surgery. Anesth Analg. 2003;97(2):390–6.
Kokki H, Karvinen M, Jekunen A. Diffusion of ketoprofen into the cerebrospinal fluid of young children. Paediatr Anaesth. 2002;12(4):313–6.
Lexi-Comp OnlineTM. Pediatric & neonatal lexi-drugs OnlineTM. Hudson: Lexi-Comp; 2013.
Knipping S, Holzhausen H, Riederer A, Bloching M. Cystic fibrosis: ultrastructural changes of nasal mucosa. Eur Arch Otorhinolaryngol. 2007;264(12):1413–8.
Polli JE, Yu LX, Cook JA, Amidon GL, Borchardt RT, Burnside BA, et al. Summary workshop report: biopharmaceutics classification system—implementation challenges and extension opportunities. J Pharm Sci. 2004;93:1375–81.
Christensson B, Nilsson-Ehle I, Ljungberg B, Linblad A, Malmborg AS, Hjelte L, et al. Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients. Antimicrob Agents Chemother. 1992;36:2512–7.
European Medicines Agency. Revised provisional priority list for studies into off-patent paediatric medicinal products. http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/document/document_detail.jsp?webContentId=WC500143970&mid=WC0b01ac058009a3dc. Accessed 29 April 2013.
Lindell-Osuagwu L, Korhonen MJ, Saano S, Helin-Tanninen M, Naaranlahti T, Kokki H. Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature. J Clin Pharm Ther. 2009;34(3):277–87. Review.
Abernethy DR, Burckart GJ. Pediatric dose selection. Clin Pharmacol Ther. 2010;87:270–1.
Mahmood I. Interspecies pharmacokinetic scaling. Rockville: Pine House; 2005.
Yazdanian M, Briggs K, Jankovsky C, Hawi A. The "high solubility" definition of the current FDA guidance on biopharmaceutical classification system may be too strict for acidic drugs. Pharm Res. 2004;21(2):293–9.
Polli JE, Ginski MJ. Human drug absorption kinetics and comparison to Caco-2 monolayer permeabilities. Pharm Res. 1998;15:47–52.
Lentz KA, Hayashi J, Lucisano LJ, Polli JE. Development of a more rapid, reduced serum culture system for Caco-2 monolayers and application to biopharmaceutics classification system. Int J Pharm. 2000;200(1):41–51.
Author information
Authors and Affiliations
Corresponding author
Additional information
Guest Editors: Divyakant Desai, John Crison, and Peter Timmins
The views expressed are that of the authors and do not represent the policy of the Agency at this time.
Rights and permissions
About this article
Cite this article
Gandhi, S.V., Rodriguez, W., Khan, M. et al. Considerations for a Pediatric Biopharmaceutics Classification System (BCS): Application to Five Drugs. AAPS PharmSciTech 15, 601–611 (2014). https://doi.org/10.1208/s12249-014-0084-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12249-014-0084-0